1
Wahlestedt Claes: Natural antisense and non-coding rna transcripts as drug targets. The Scripps Research Institute, Wahlestedt Claes, ZACHARIADES Nicholas A, August 2, 2007: WO/2007/087113 (89 worldwide citation)

Small interfering RNA (siRNA) knock down antisense transcripts, and regulate the expression of their sense partners. This regulation can either be discordant (antisense knockdown results in sense transcript elevation) or concordant (antisense knockdown results in concomitant sense transcript reducti ...


2
Claes Wahlestedt: Natural antisense and non-coding RNA transcripts as drug targets. The Scripps Research Institute, Wilson Sonsini Goodrich & Rosati, October 16, 2012: US08288354 (11 worldwide citation)

Small interfering RNA (siRNA) knock down antisense transcripts, and regulate the expression of their sense partners. This regulation can either be discordant (antisense knockdown results in sense transcript elevation) or concordant (antisense knockdown results in concomitant sense transcript reducti ...


3
Claes Wahlestedt: Natural antisense and non-coding RNA transcripts as drug targets. The Scripps Research Institute, Wilson Sonsini Goodrich & Rosati, October 31, 2017: US09803195

Small interfering RNA (siRNA) knock down antisense transcripts, and regulate the expression of their sense partners. This regulation can either be discordant (antisense knockdown results in sense transcript elevation) or concordant (antisense knockdown results in concomitant sense transcript reducti ...


4
Joseph Collard, Olga Khorkova Sherman: Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO. CuRNA, CuRNA, Monte R Browder, September 19, 2017: US09765336

Oligonucleotide compounds modulate expression and/or function of Erythropoietin (EPO) polynucleotides and encoded products thereof. Methods for treating diseases associated with Erythropoietin (EPO) comprise administering one or more oligonucleotide compounds designed to inhibit the EPO natural anti ...


5
Wahlestedt Claes: Natural antisense and non-coding RNA transcripts as drug targets. Scripps Research Inst, Zhou Jianqiu, Wang Fengdong, May 20, 2009: CN200680053539

Small interfering RNA (siRNA) knock down antisense transcripts, and regulate the expression of their sense partners. This regulation can either be discordant (antisense knockdown results in sense transcript elevation) or concordant (antisense knockdown results in concomitant sense transcript reducti ...


6
Wahlestedt Claes: Natural antisense and non-coding rna transcripts as drug targets. Scripps Research Inst, October 8, 2008: EP1976567-A2

Small interfering RNA (siRNA) knock down antisense transcripts, and regulate the expression of their sense partners. This regulation can either be discordant (antisense knockdown results in sense transcript elevation) or concordant (antisense knockdown results in concomitant sense transcript reducti ...


7
Claes Wahlestedt: Natural antisense and non-coding rna transcripts as drug targets. Wilson Sonsini Goodrich & Rosati, October 15, 2009: US20090258925-A1

Small interfering RNA (siRNA) knock down antisense transcripts, and regulate the expression of their sense partners. This regulation can either be discordant (antisense knockdown results in sense transcript elevation) or concordant (antisense knockdown results in concomitant sense transcript reducti ...


8
NATURAL ANTISENSE AND NON-CODING RNA TRANSCRIPTS AS DRUG TARGETS. The Scripps Research Institute, February 28, 2013: US20130053428-A1

Small interfering RNA (siRNA) knock down antisense transcripts, and regulate the expression of their sense partners. This regulation can either be discordant (antisense knockdown results in sense transcript elevation) or concordant (antisense knockdown results in concomitant sense transcript reducti ...


9
TREATMENT OF ERYTHROPOIETIN (EPO) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO EPO. January 11, 2018: US20180010131-A1

Oligonucleotide compounds modulate expression and/or function of Erythropoietin (EPO) polynucleotides and encoded products thereof. Methods for treating diseases associated with Erythropoietin (EPO) comprise administering one or more oligonucleotide compounds designed to inhibit the EPO natural anti ...